Correlation of β2-microglobulin with postoperative delirium and 3-year mortality undergoing knee or hip replacement surgery: a prospective cohort study

β2-微球蛋白与膝关节或髋关节置换术后谵妄及3年死亡率的相关性:一项前瞻性队列研究

阅读:2

Abstract

INTRODUCTION: Postoperative delirium (POD) is a commonly occurring condition in the postoperative period. Therefore, the study intends to investigate the relationship between B(2)M and POD and the effect of B(2)M levels on three-year postoperative mortality in patients with POD. METHODS: Postoperatively, the Confusion Assessment Method (CAM) and the Monumental Delirium Assessment Scale (MDAS) were used to assess the incidence and severity of POD. Preoperative plasma B(2)M levels were measured utilizing a latex-enhanced immunoturbidimetric assay. Total tau protein (T-tau), phosphorylated tau protein (P-tau), and amyloid β plaque 42 (Aβ(42)) were detected in preoperative cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay. Logistic regression equations were applied to examine the risk factors linked to POD. Patients presenting with POD were grouped according to B(2)M level and followed up for 3 years postoperatively for their survival and Kaplan-Meier survival curves were plotted. RESULTS: The prevalence of POD was 7.23%. Serum B(2)M levels were higher in POD patients compared to non-POD (NPOD) patients (p = 0.01). The results of the logistic regression analysis indicated that B(2)M (OR = 1.394, 95% CI = 1.017-1.910, p = 0.002) and T-tau (OR = 1.006, 95% CI = 1.002-1.011, p = 0.007) posed a risk for POD. B(2)M and POD were partially associated through the mediation of CSF T-tau (10.0%). The K-M survival curves showed that patients with high B(2)M who developed POD had a higher mortality rate 3 years after surgery (p = 0.031). CONCLUSION: In summary, B(2)M may be a risk factor for POD, which might be mediated in part by CSF T-tau.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。